Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with…
PARIS, April 27, 2026 /PRNewswire/ -- A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5…
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including…
Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the…
SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF), Sinocare presented its latest advancements…
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to…
Nairobi event takes place May 7-9 STOCKHOLM, March 30, 2026 /PRNewswire/ -- IFPA (The International Federation of Psoriasis Associations) –…
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…
March 10, 2026 08:05 ET | Source: NKGen Biotech, Inc. SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen…
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease…